JP7174960B2 - 抗腫瘍t細胞応答増強剤 - Google Patents
抗腫瘍t細胞応答増強剤 Download PDFInfo
- Publication number
- JP7174960B2 JP7174960B2 JP2021074601A JP2021074601A JP7174960B2 JP 7174960 B2 JP7174960 B2 JP 7174960B2 JP 2021074601 A JP2021074601 A JP 2021074601A JP 2021074601 A JP2021074601 A JP 2021074601A JP 7174960 B2 JP7174960 B2 JP 7174960B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- receptor
- cells
- antibodies
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
なお、本出願の発明に関連する先行技術文献情報を以下に示す。
〔1〕インターロイキン6(IL-6)阻害剤、および/または、ゲムシタビン若しくはその塩を含有する、担癌生体の抗腫瘍T細胞応答増強用組成物。
〔2〕IL-6阻害剤、および、ゲムシタビン若しくはその塩を併用して投与することを特徴とする、〔1〕に記載の抗腫瘍T細胞応答増強用組成物。
〔3〕前記IL-6阻害剤がIL-6受容体に結合する物質である、〔1〕または〔2〕に記載の組成物。
〔4〕前記IL-6受容体に結合する物質が抗IL-6受容体抗体である、〔3〕に記載の組成物。
〔5〕前記抗IL-6受容体抗体がキメラ抗体、ヒト化抗体またはヒト抗体である、〔4〕に記載の組成物。
〔6〕前記ゲムシタビン若しくはその塩がゲムシタビン塩酸塩である〔1〕~〔5〕に記載の組成物。
〔7〕IL-6阻害剤、および/または、ゲムシタビン若しくはその塩を担癌生体に投与する工程を含む、抗腫瘍T細胞応答を増強する方法。
〔8〕前記IL-6阻害剤がIL-6受容体に結合する物質である〔7〕に記載の方法。
〔9〕前記IL-6受容体に結合する物質が抗IL-6受容体抗体である〔8〕に記載の方法。
〔10〕前記抗IL-6受容体抗体がキメラ抗体、ヒト化抗体またはヒト抗体である〔9〕に記載の方法。
〔11〕前記ゲムシタビン若しくはその塩がゲムシタビン塩酸塩である〔7〕~〔10〕に記載の方法。
〔12〕担癌生体における抗腫瘍T細胞応答の増強に使用するための、IL-6阻害剤。
〔13〕IL-6阻害剤およびゲムシタビン若しくはその塩の併用により抗腫瘍T細胞応答を増強することを特徴とする、〔12〕に記載の阻害剤。
〔14〕前記IL-6阻害剤がIL-6受容体に結合する物質である〔13〕に記載の阻害剤。
〔15〕前記IL-6受容体に結合する物質が抗IL-6受容体抗体である〔14〕に記載の阻害剤。
〔16〕前記抗IL-6受容体抗体がキメラ抗体、ヒト化抗体またはヒト抗体である〔15〕に記載の阻害剤。
〔17〕前記ゲムシタビン若しくはその塩がゲムシタビン塩酸塩である〔13〕~〔16〕に記載の阻害剤。
なお本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
メチルコラントレン誘発偏平上皮癌細胞株 CMC-1 (2x106)をBALB/cマウスに皮内接種し、5日後よりGEM (ジェムザール:塩酸ゲムシタビン)(120 mg/kg)を1週間毎に腹腔内投与した。腫瘍の増殖を2日毎に計測し、GEMによる抗腫瘍効果を評価した。その結果を図1に示した。
CMC-1接種後30日の担癌マウスにGEMを接種し、48時間後、脾臓内の各細胞群の絶対数をフローサイトメトリーにて解析した。その結果を図2に示した。CMC-1接種後30日の担癌マウスにサイクロフォスファミド (CY)(60 mg/kg)、フルオロ-5-ウラシル(5-FU) (120 mg/kg)、GEMを腹腔内投与した。48時間後、脾臓内CD8+細胞を単離し、固層化抗CD3抗体 (2 μg/ml)にて60時間刺激後の増殖能を3H取り込み試験にて評価した。その結果を図3に示した。
これらの結果から、GEMが免疫抑制細胞を排除し、担癌生体のCD8+T細胞に対して優れた増殖促進効果を有することが示された。当該効果は、CYや5-FUでは確認することができなかった。また、腫瘍増殖抑制効果を有することも確認することができた。
CMC-1(2x106)をBALB/cマウスに皮内接種後、5日後よりGEM (120 mg/kg)を1週間毎に腹腔内投与、抗CD8抗体 (250 μg)を3日毎に静脈内投与し、腫瘍径を2日毎に計測した。その結果を図4に示した。
マウス肺癌細胞株 LLCに卵白アルブミン (OVA)遺伝子を導入したLLC-OVA (2x106)をC57BL6マウスに皮内接種し、5日後にGEM (120 mg/kg)を腹腔内投与した。9日後に、所属リンパ節を採取し、OVA特異的CD8+細胞傷害性T細胞の割合をフローサイトメトリーにて評価した。その結果を図5に示した。
これらの結果から、GEMによるCD8+T細胞の活性増加を介して、抗腫瘍効果が認められていることを確認することができた。
メチルコラントレン誘発線維芽肉腫細胞株CMC-G4 (2x106)をBALB/cマウスに皮内接種し、1週間後および2週間後の血清中IL-6濃度をELISAにて測定した。その結果を図6に示した。CMC-G4を皮内接種後、3日毎に抗IL-6受容体抗体(MR16-1:Tamura, T. et al. Proc. Natl. Acad. Sci. USA (1993) 90, 11924-11928) (250 μg)を静脈内投与した。28日後に脾臓細胞を採取し、抗CD3抗体 (2 μg/ml)、あるいはコンカナバリンA (ConA:2.5μg/ml)存在下で36時間培養後の培養上清中IFN-γ濃度をELISAにて測定した。その結果を図7に示した。さらに、腫瘍径を2日毎に測定し、腫瘍増殖抑制効果を評価した。その結果を図8に示した。
これらの結果から、抗IL-6受容体抗体が担癌生体におけるIFN-γの産生を促進させる効果を有していることが明らかとなった。当該結果から、抗IL-6受容体抗体もGEM同様に免疫担当細胞に対して優れた活性化促進効果を有することが示された。また、腫瘍増殖抑制効果を有することも確認することができた。
CMC-G4 (2x106)をBALB/cマウスに皮内接種後、6日後からGEM (120 mg/kg)を1週間毎に腹腔内投与、抗IL-6受容体抗体 MR16-1 (200 μg)を3日毎に静脈内投与し、腫瘍径を2日毎に計測した。その結果を図9に示した。
当該結果から、ゲムシタビン(GEM)および抗IL-6受容体抗体(MR16-1)を併用することにより、それぞれ単独で投与したときよりも優れた抗腫瘍効果が得られることが明らかとなった。
Claims (3)
- 抗 インターロイキン6(IL-6)受容体抗体を含有する、担癌生体の抗腫瘍T細胞応答増強用組成物であって、前記癌は線維芽肉腫である、組成物。
- 前記抗IL-6受容体抗体がキメラ抗体、ヒト化抗体またはヒト抗体である、請求項1に記載の組成物。
- 前記抗IL-6受容体抗体がTocilizumabである、請求項1に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022172859A JP2022187002A (ja) | 2010-05-28 | 2022-10-28 | 抗腫瘍t細胞応答増強剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010122951 | 2010-05-28 | ||
JP2010122951 | 2010-05-28 | ||
JP2016229667A JP6952454B2 (ja) | 2010-05-28 | 2016-11-28 | 抗腫瘍t細胞応答増強剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016229667A Division JP6952454B2 (ja) | 2010-05-28 | 2016-11-28 | 抗腫瘍t細胞応答増強剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022172859A Division JP2022187002A (ja) | 2010-05-28 | 2022-10-28 | 抗腫瘍t細胞応答増強剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021105067A JP2021105067A (ja) | 2021-07-26 |
JP7174960B2 true JP7174960B2 (ja) | 2022-11-18 |
Family
ID=45004034
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517328A Active JP6051049B2 (ja) | 2010-05-28 | 2011-05-27 | 抗腫瘍t細胞応答増強剤 |
JP2016229667A Active JP6952454B2 (ja) | 2010-05-28 | 2016-11-28 | 抗腫瘍t細胞応答増強剤 |
JP2021074601A Active JP7174960B2 (ja) | 2010-05-28 | 2021-04-27 | 抗腫瘍t細胞応答増強剤 |
JP2022172859A Pending JP2022187002A (ja) | 2010-05-28 | 2022-10-28 | 抗腫瘍t細胞応答増強剤 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012517328A Active JP6051049B2 (ja) | 2010-05-28 | 2011-05-27 | 抗腫瘍t細胞応答増強剤 |
JP2016229667A Active JP6952454B2 (ja) | 2010-05-28 | 2016-11-28 | 抗腫瘍t細胞応答増強剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022172859A Pending JP2022187002A (ja) | 2010-05-28 | 2022-10-28 | 抗腫瘍t細胞応答増強剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9539322B2 (ja) |
EP (2) | EP4115906A1 (ja) |
JP (4) | JP6051049B2 (ja) |
DK (1) | DK2578231T3 (ja) |
ES (1) | ES2932398T3 (ja) |
HR (1) | HRP20221490T1 (ja) |
HU (1) | HUE060454T2 (ja) |
PL (1) | PL2578231T3 (ja) |
PT (1) | PT2578231T (ja) |
RS (1) | RS63800B1 (ja) |
SI (1) | SI2578231T1 (ja) |
WO (1) | WO2011149051A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US8398980B2 (en) | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
BRPI0617664B8 (pt) * | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
EP3135298B1 (en) * | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
CN101495146B (zh) * | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
TWI438208B (zh) * | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
KR101665729B1 (ko) | 2008-06-05 | 2016-10-12 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신경침윤 억제제 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
DK2578231T3 (da) | 2010-05-28 | 2022-12-12 | Chugai Pharmaceutical Co Ltd | Antitumor-t-celle-reaktionsforstærker |
CN103476793A (zh) | 2010-11-08 | 2013-12-25 | 基因技术公司 | 皮下施用的抗-il-6受体抗体 |
US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
BR112015032960B1 (pt) | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
TWI805046B (zh) | 2015-02-27 | 2023-06-11 | 日商中外製藥股份有限公司 | Il-6受體抗體用於製備醫藥組成物的用途 |
PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
WO2016195088A1 (ja) * | 2015-06-04 | 2016-12-08 | 国立研究開発法人 国立精神・神経医療研究センター | Il-6阻害剤を有効成分とする精神疾患治療剤 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
JP2008297315A (ja) | 1994-10-21 | 2008-12-11 | Chuzo Kishimoto | Il−6産生に起因する疾患の治療剤 |
WO2009148148A1 (ja) | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | 神経浸潤抑制剤 |
WO2011013786A1 (ja) | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
JP6051049B2 (ja) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
SG42954A1 (en) | 1989-07-20 | 1997-10-17 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
JP2898064B2 (ja) | 1989-08-03 | 1999-05-31 | 忠三 岸本 | ヒトgp130蛋白質 |
JPH03155795A (ja) | 1989-11-13 | 1991-07-03 | Chuzo Kishimoto | マウス・インターロイキン―6レセプター蛋白質 |
JP2898040B2 (ja) | 1990-01-26 | 1999-05-31 | 忠三 岸本 | gp130蛋白質に対する抗体 |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992019759A1 (en) | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
AU673985B2 (en) | 1991-11-08 | 1996-12-05 | Board Of Trustees Of The Leland Stanford Junior University | CD8 binding domain peptides |
ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
JP3525221B2 (ja) | 1993-02-17 | 2004-05-10 | 味の素株式会社 | 免疫抑制剤 |
US5468772A (en) | 1993-03-10 | 1995-11-21 | Pharmagenesis, Inc. | Tripterinin compound and method |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
AU6808194A (en) | 1993-05-31 | 1994-12-20 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
JP3614183B2 (ja) | 1993-05-31 | 2005-01-26 | 中外製薬株式会社 | ヒトインターロイキン−6に対する再構成ヒト抗体 |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
US6074643A (en) | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
US6083501A (en) | 1994-06-07 | 2000-07-04 | Toray Industries, Inc. | Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases |
US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
RU2147443C1 (ru) | 1994-10-07 | 2000-04-20 | Чугаи Сейяку Кабусики Кайся | Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента |
IT1274350B (it) | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
IT1274782B (it) | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
KR100252743B1 (ko) | 1994-12-29 | 2000-09-01 | 나가야마 오사무 | Il-6 안타고니스트를 함유하는 항종양제의 작용증강제 |
ES2264135T3 (es) | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
EP0817794A1 (en) | 1995-03-31 | 1998-01-14 | Jakob Bohr | Method for protein folding |
FR2733250B1 (fr) | 1995-04-21 | 1997-07-04 | Diaclone | Anticorps monoclonaux anti-gp130, et leurs utilisations |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
RU2127117C1 (ru) | 1996-06-26 | 1999-03-10 | Филиппова Ольга Всеволодовна | Способ лечения ишемической болезни сердца |
GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
AU735592B2 (en) | 1997-05-17 | 2001-07-12 | Biogen Idec Ma Inc. | Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
JPH11180873A (ja) | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
JP4698652B2 (ja) | 1998-03-17 | 2011-06-08 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤 |
CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
EP0972780A1 (en) | 1998-05-18 | 2000-01-19 | Applied Research Systems ARS Holding N.V. | Il-6 antagonist peptides |
ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
JP4799516B2 (ja) | 1998-08-24 | 2011-10-26 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する膵炎の予防又は治療剤 |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
ES2250154T3 (es) | 1999-07-16 | 2006-04-16 | Kissei Pharmaceutical Co., Ltd. | Agentes que inhiben las reacciones de rechazo cronico despues de un transplante de organo. |
WO2001045678A2 (de) | 1999-12-21 | 2001-06-28 | Id Pharma Gmbh | Arzneimittel, verfahren zu dessen herstellung und dessen verwendung |
US6413663B1 (en) | 2000-06-29 | 2002-07-02 | Graftech Inc. | Fluid permeable flexible graphite fuel cell electrode |
CN1259973C (zh) | 2000-10-25 | 2006-06-21 | 中外制药株式会社 | 含有il-6拮抗剂作为有效成分的牛皮癣的预防或治疗剂 |
AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
US20050182007A1 (en) | 2001-05-18 | 2005-08-18 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA) |
IL161968A0 (en) | 2001-11-14 | 2005-11-20 | Centocor Inc | Anti-il-6 antibodies, compositions, methods and uses |
FR2833011B1 (fr) | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
DE10231655A1 (de) | 2002-07-12 | 2004-02-26 | Blasticon Biotechnologische Forschung Gmbh | Transplantat-Akzeptanz induzierende Zellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
AU2003290682A1 (en) | 2002-11-15 | 2004-06-15 | Centocor, Inc. | Anti-angiogenic uses of il-6 antagonists |
KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
WO2004071404A2 (en) | 2003-02-04 | 2004-08-26 | Centocor Inc. | Use of il-6 antagonists in combination with steroids to enhance apoptosis |
CN100340294C (zh) | 2003-02-24 | 2007-10-03 | 中外制药株式会社 | 含有白介素6拮抗剂的脊髓损伤治疗剂 |
US20040208876A1 (en) | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
EP3168304A1 (en) | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
CN101407471A (zh) | 2003-08-29 | 2009-04-15 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
JP4960096B2 (ja) | 2003-09-22 | 2012-06-27 | ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−6の生物学的効果を減じる化合物の使用 |
US20060193772A1 (en) | 2003-09-24 | 2006-08-31 | Atsushi Ochiai | Drugs for treating cancer |
NZ546557A (en) | 2003-10-17 | 2010-01-29 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for mesothelioma comprising interleukin-6 |
KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Hgf의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
JP4609877B2 (ja) | 2004-03-30 | 2011-01-12 | 塩野義製薬株式会社 | 慢性拒絶反応抑制剤 |
PL1772145T3 (pl) | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
WO2006135385A2 (en) | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
JP4523358B2 (ja) * | 2004-08-09 | 2010-08-11 | モリヤマ化成株式会社 | 固形石鹸用泡立てネット及びその製造方法 |
US7884196B2 (en) | 2004-10-06 | 2011-02-08 | Oliver Lawless | Vaccine composition comprising methylated DNA and immunomodulatory motifs |
CA2591059C (en) | 2004-12-28 | 2018-11-06 | Innate Pharma | Monoclonal antibodies against nkg2a |
PA8672101A1 (es) | 2005-04-29 | 2006-12-07 | Centocor Inc | Anticuerpos anti-il-6, composiciones, métodos y usos |
WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
KR20080090484A (ko) | 2005-12-30 | 2008-10-08 | 메르크 파텐트 게엠베하 | GP130 에 대한, IL-6Rα 와 복합체를 형성한 IL-6의 결합을 방해하는 항-IL-6 항체 |
EP3135298B1 (en) | 2006-01-27 | 2018-06-06 | Keio University | Therapeutic agents for diseases involving choroidal neovascularization |
CN101495146B (zh) | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
US20080081041A1 (en) | 2006-09-29 | 2008-04-03 | Jeffrey Nemeth | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer |
TWI438208B (zh) | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
PL2164514T3 (pl) * | 2007-05-21 | 2017-08-31 | Alderbio Holdings Llc | Przeciwciała przeciwko IL-6 i ich zastosowanie |
WO2009010539A2 (en) | 2007-07-19 | 2009-01-22 | Ablynx. N.V. | Receptor for interleukin-6 (il-6) from macaca fascicularis |
PH12018501459A1 (en) | 2007-09-26 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
CL2008002885A1 (es) | 2007-09-26 | 2010-07-02 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
KR101314880B1 (ko) | 2009-03-19 | 2013-10-04 | 추가이 세이야쿠 가부시키가이샤 | 관절류머티즘 치료제 |
WO2011149046A1 (ja) | 2010-05-28 | 2011-12-01 | 独立行政法人国立がん研究センター | 膵癌治療剤 |
-
2011
- 2011-05-27 DK DK11786748.1T patent/DK2578231T3/da active
- 2011-05-27 HU HUE11786748A patent/HUE060454T2/hu unknown
- 2011-05-27 EP EP22192455.8A patent/EP4115906A1/en active Pending
- 2011-05-27 ES ES11786748T patent/ES2932398T3/es active Active
- 2011-05-27 US US13/700,355 patent/US9539322B2/en active Active
- 2011-05-27 PT PT117867481T patent/PT2578231T/pt unknown
- 2011-05-27 HR HRP20221490TT patent/HRP20221490T1/hr unknown
- 2011-05-27 RS RS20221126A patent/RS63800B1/sr unknown
- 2011-05-27 JP JP2012517328A patent/JP6051049B2/ja active Active
- 2011-05-27 EP EP11786748.1A patent/EP2578231B1/en active Active
- 2011-05-27 PL PL11786748.1T patent/PL2578231T3/pl unknown
- 2011-05-27 WO PCT/JP2011/062209 patent/WO2011149051A1/ja active Application Filing
- 2011-05-27 SI SI201132068T patent/SI2578231T1/sl unknown
-
2016
- 2016-11-28 JP JP2016229667A patent/JP6952454B2/ja active Active
-
2021
- 2021-04-27 JP JP2021074601A patent/JP7174960B2/ja active Active
-
2022
- 2022-10-28 JP JP2022172859A patent/JP2022187002A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008297315A (ja) | 1994-10-21 | 2008-12-11 | Chuzo Kishimoto | Il−6産生に起因する疾患の治療剤 |
WO2007061029A1 (ja) | 2005-11-25 | 2007-05-31 | Keio University | 前立腺癌治療剤 |
WO2009148148A1 (ja) | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | 神経浸潤抑制剤 |
WO2011013786A1 (ja) | 2009-07-31 | 2011-02-03 | Maeda Shin | 癌の転移抑制剤 |
JP6051049B2 (ja) | 2010-05-28 | 2016-12-21 | 中外製薬株式会社 | 抗腫瘍t細胞応答増強剤 |
Non-Patent Citations (7)
Title |
---|
Annual Review 免疫,1999年,VOL.1999,P.257-269 |
Clin. Cancer Res.,日本,2009年09月01日,Vol.15, No.17,pp.5426-5434 |
CLINICAL CANCER RESEARCH,2005年,VOL.11,P.6713-6721 |
GASTROENTEROLOGY,2005年04月,VOL.128, NO.4, SUPPL.2,P.A-30,ABSTRACT 165 |
JOURNAL OF HEPATOLOGY,2006年,VOL.44,P.1055-1065 |
Otolaryngol Head Neck Surg.,米国,2004年,Vol.131,pp.573-576 |
基盤的癌免疫研究会総会抄録,2006年,VOL.10th,P.49 |
Also Published As
Publication number | Publication date |
---|---|
EP2578231B1 (en) | 2022-10-26 |
JPWO2011149051A1 (ja) | 2013-07-25 |
PL2578231T3 (pl) | 2023-01-16 |
ES2932398T3 (es) | 2023-01-18 |
US9539322B2 (en) | 2017-01-10 |
EP2578231A4 (en) | 2013-10-30 |
JP2017061541A (ja) | 2017-03-30 |
JP6051049B2 (ja) | 2016-12-21 |
HUE060454T2 (hu) | 2023-03-28 |
WO2011149051A1 (ja) | 2011-12-01 |
JP2022187002A (ja) | 2022-12-15 |
SI2578231T1 (sl) | 2023-01-31 |
RS63800B1 (sr) | 2022-12-30 |
HRP20221490T1 (hr) | 2023-02-03 |
US20130202588A1 (en) | 2013-08-08 |
EP4115906A1 (en) | 2023-01-11 |
DK2578231T3 (da) | 2022-12-12 |
JP6952454B2 (ja) | 2021-10-20 |
EP2578231A1 (en) | 2013-04-10 |
PT2578231T (pt) | 2022-12-02 |
JP2021105067A (ja) | 2021-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7174960B2 (ja) | 抗腫瘍t細胞応答増強剤 | |
US20220175919A1 (en) | Therapeutic agents for pancreatic cancer | |
JP5264752B2 (ja) | インターロイキン6受容体阻害剤を有効成分とする移植片対宿主病治療剤 | |
JP5544290B2 (ja) | 神経浸潤抑制剤 | |
US8945558B2 (en) | Methods for treating myocardial infarction comprising administering an IL-6 inhibitor | |
JP5424330B2 (ja) | インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤 | |
US20090269335A1 (en) | Therapeutic agent for prostate cancer | |
JP2010095445A (ja) | Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220601 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220729 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221003 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221028 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7174960 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |